New Research Reveals Updated Patient Preferences on Digital Health Technology
October 18 2019 - 8:00AM
Business Wire
The majority of Americans believe technology
has improved certain aspects of their healthcare; 8 in 10 agree
technology has made seeking treatment easier
ResMed (NYSE: RMD, ASX: RMD) today announced results from a
company-led survey, revealing new patient preferences on digital
health technology. The survey highlights a reason for optimism that
the markets for digital health technology will only continue to
grow.
The survey of a nationally representative sample of 3,000
Americans, conducted in partnership with Edelman Intelligence,
revealed that the use of – and confidence in – remote digital
health technology is widespread: 56% of those surveyed currently
monitor their health with at least one digital data collection
tool.
Also, 60% of people attempt to diagnose themselves after
browsing symptoms on the Internet – including 76% of
Millennials.
Perhaps more surprising, remote digital health technology seems
to have deepened people’s connection with their physicians rather
than distanced them from one another. Over half of those surveyed
agree that technology has improved their relationship with their
primary care provider, and many would like to be able to
communicate with their physician more often. They also see an
increased opportunity to accomplish this, with 68% wanting
technology to play a larger role in sharing real-time medical
information with their physician.
“Apps and other digital tools now provide easy, secure access to
our own health data and our doctors at all times,” explains Carlos
M. Nunez, M.D., ResMed’s Chief Medical Officer. “These real-world
data can reveal insights that help improve the use of a home-based
therapy or may spark a talk with a doctor that helps patients get
the most from their therapy for better results. Meanwhile,
clinicians with remote access to patients’ data can monitor them
more easily, quickly reaching out to those who need support.
Medical researchers can analyze large data sets to uncover findings
that may lead to new best practices that are applicable across
populations of patients. All of these benefits are changing the way
we all receive care today, improving the quality of care for
millions and increasing healthcare providers’ efficiency.”
With over 10 million cloud-connectable sleep apnea and
respiratory care devices in patients’ homes, ResMed knows the
importance of helping people understand how digital health
technology can positively impact their health:
- 87% of sleep apnea devices users are adherent on therapy when
remotely and self-monitored, compared to roughly 50% on non-cloud
connected devices.1
- A digital sensor tracking a patient’s inhaler use for asthma or
COPD can improve adherence up to 58%, increase symptom-free days
48%, and reduce emergency room visits by 53%.2-3
“These survey findings highlight the need to keep educating the
public on the benefits of remote monitoring and other digital
tools, as well as the viability of out-of-hospital care, as
technology allows patients and physicians to more efficiently
collaborate on improving health outcomes as a team,” explains
Nunez. “ResMed’s connected health devices and software platforms
supporting out-of-hospital care are each integral parts of this
dynamic shift, and I believe they are crucial in helping improve
the lives of hundreds of millions people around the world.”
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD, and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease, and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit ResMed.com
and follow @ResMed.
1 Malhotra A et al. Chest 2018 2 Van Sickle D et al. Eur Resp J
2016 3 Barrett M et al. Health Affairs 2018
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191018005081/en/
For media Aaron Murphy +1 415.229.3331
aaron.murphy@edelman.com
For investors Amy Wakeham +1 858.836.5000
investorrelations@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2024 to May 2024
Resmed (ASX:RMD)
Historical Stock Chart
From May 2023 to May 2024